Global Inhalational Isoflurane 麻豆原创 Growth 2024-2030

Publication ID:

LPI11247116

Publication Date:

November 14, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Isoflurane is a widely used inhalational anesthetic agent employed in general anesthesia. It is a halogenated ether with the chemical formula C鈧僅鈧侰lF鈧匫, and it functions by inducing a reversible loss of consciousness and sensation in patients undergoing surgical procedures. Isoflurane acts on the central nervous system by enhancing the inhibitory effects of neurotransmitters and disrupting neural pathways that mediate awareness and sensation. It is favored in clinical settings due to its stable cardiovascular effects, ease of control, and minimal metabolism by the liver. Its administration requires specialized equipment to ensure accurate delivery and maintenance of the desired anesthetic depth.
The global Inhalational Isoflurane market size is projected to grow from US$ 20.5 million in 2024 to US$ 26.5 million in 2030; it is expected to grow at a CAGR of 4.3% from 2024 to 2030.
The 鈥淚nhalational Isoflurane Industry Forecast鈥� looks at past sales and reviews total world Inhalational Isoflurane sales in 2023, providing a comprehensive analysis by region and market sector of projected Inhalational Isoflurane sales for 2024 through 2030. With Inhalational Isoflurane sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Inhalational Isoflurane industry.
This Insight Report provides a comprehensive analysis of the global Inhalational Isoflurane landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Inhalational Isoflurane portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Inhalational Isoflurane market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Inhalational Isoflurane and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Inhalational Isoflurane.
United States market for Inhalational Isoflurane is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Inhalational Isoflurane is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Inhalational Isoflurane is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Inhalational Isoflurane players cover KALBE PHARMA, Baxter, Neon Laboratories, AbbVie, Piramal, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Inhalational Isoflurane market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Generic Drugs
Brand Drug
Segmentation by Application:
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
KALBE PHARMA
Baxter
Neon Laboratories
AbbVie
Piramal
LAB UNKNOWN
Viatris
PT Novell Pharmaceutical
Sedana Medical
Lunan Beite
Key Questions Addressed in this Report
What is the 10-year outlook for the global Inhalational Isoflurane market?
What factors are driving Inhalational Isoflurane market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Inhalational Isoflurane market opportunities vary by end market size?
How does Inhalational Isoflurane break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Inhalational Isoflurane Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Inhalational Isoflurane by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Inhalational Isoflurane by Country/Region, 2019, 2023 & 2030
2.2 Inhalational Isoflurane Segment by Type
2.2.1 Generic Drugs
2.2.2 Brand Drug
2.3 Inhalational Isoflurane Sales by Type
2.3.1 Global Inhalational Isoflurane Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Inhalational Isoflurane Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Inhalational Isoflurane Sale Price by Type (2019-2024)
2.4 Inhalational Isoflurane Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Inhalational Isoflurane Sales by Application
2.5.1 Global Inhalational Isoflurane Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Inhalational Isoflurane Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Inhalational Isoflurane Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Inhalational Isoflurane Breakdown Data by Company
3.1.1 Global Inhalational Isoflurane Annual Sales by Company (2019-2024)
3.1.2 Global Inhalational Isoflurane Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Inhalational Isoflurane Annual Revenue by Company (2019-2024)
3.2.1 Global Inhalational Isoflurane Revenue by Company (2019-2024)
3.2.2 Global Inhalational Isoflurane Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Inhalational Isoflurane Sale Price by Company
3.4 Key Manufacturers Inhalational Isoflurane Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Inhalational Isoflurane Product Location Distribution
3.4.2 Players Inhalational Isoflurane Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Inhalational Isoflurane by Geographic Region
4.1 World Historic Inhalational Isoflurane 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Inhalational Isoflurane Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Inhalational Isoflurane Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Inhalational Isoflurane 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Inhalational Isoflurane Annual Sales by Country/Region (2019-2024)
4.2.2 Global Inhalational Isoflurane Annual Revenue by Country/Region (2019-2024)
4.3 Americas Inhalational Isoflurane Sales Growth
4.4 APAC Inhalational Isoflurane Sales Growth
4.5 Europe Inhalational Isoflurane Sales Growth
4.6 Middle East & Africa Inhalational Isoflurane Sales Growth
5 Americas
5.1 Americas Inhalational Isoflurane Sales by Country
5.1.1 Americas Inhalational Isoflurane Sales by Country (2019-2024)
5.1.2 Americas Inhalational Isoflurane Revenue by Country (2019-2024)
5.2 Americas Inhalational Isoflurane Sales by Type (2019-2024)
5.3 Americas Inhalational Isoflurane Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Inhalational Isoflurane Sales by Region
6.1.1 APAC Inhalational Isoflurane Sales by Region (2019-2024)
6.1.2 APAC Inhalational Isoflurane Revenue by Region (2019-2024)
6.2 APAC Inhalational Isoflurane Sales by Type (2019-2024)
6.3 APAC Inhalational Isoflurane Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Inhalational Isoflurane by Country
7.1.1 Europe Inhalational Isoflurane Sales by Country (2019-2024)
7.1.2 Europe Inhalational Isoflurane Revenue by Country (2019-2024)
7.2 Europe Inhalational Isoflurane Sales by Type (2019-2024)
7.3 Europe Inhalational Isoflurane Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Inhalational Isoflurane by Country
8.1.1 Middle East & Africa Inhalational Isoflurane Sales by Country (2019-2024)
8.1.2 Middle East & Africa Inhalational Isoflurane Revenue by Country (2019-2024)
8.2 Middle East & Africa Inhalational Isoflurane Sales by Type (2019-2024)
8.3 Middle East & Africa Inhalational Isoflurane Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Inhalational Isoflurane
10.3 Manufacturing Process Analysis of Inhalational Isoflurane
10.4 Industry Chain Structure of Inhalational Isoflurane
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Inhalational Isoflurane Distributors
11.3 Inhalational Isoflurane Customer
12 World Forecast Review for Inhalational Isoflurane by Geographic Region
12.1 Global Inhalational Isoflurane 麻豆原创 Size Forecast by Region
12.1.1 Global Inhalational Isoflurane Forecast by Region (2025-2030)
12.1.2 Global Inhalational Isoflurane Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Inhalational Isoflurane Forecast by Type (2025-2030)
12.7 Global Inhalational Isoflurane Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 KALBE PHARMA
13.1.1 KALBE PHARMA Company Information
13.1.2 KALBE PHARMA Inhalational Isoflurane Product Portfolios and Specifications
13.1.3 KALBE PHARMA Inhalational Isoflurane Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 KALBE PHARMA Main Business Overview
13.1.5 KALBE PHARMA Latest Developments
13.2 Baxter
13.2.1 Baxter Company Information
13.2.2 Baxter Inhalational Isoflurane Product Portfolios and Specifications
13.2.3 Baxter Inhalational Isoflurane Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Baxter Main Business Overview
13.2.5 Baxter Latest Developments
13.3 Neon Laboratories
13.3.1 Neon Laboratories Company Information
13.3.2 Neon Laboratories Inhalational Isoflurane Product Portfolios and Specifications
13.3.3 Neon Laboratories Inhalational Isoflurane Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Neon Laboratories Main Business Overview
13.3.5 Neon Laboratories Latest Developments
13.4 AbbVie
13.4.1 AbbVie Company Information
13.4.2 AbbVie Inhalational Isoflurane Product Portfolios and Specifications
13.4.3 AbbVie Inhalational Isoflurane Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 AbbVie Main Business Overview
13.4.5 AbbVie Latest Developments
13.5 Piramal
13.5.1 Piramal Company Information
13.5.2 Piramal Inhalational Isoflurane Product Portfolios and Specifications
13.5.3 Piramal Inhalational Isoflurane Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Piramal Main Business Overview
13.5.5 Piramal Latest Developments
13.6 LAB UNKNOWN
13.6.1 LAB UNKNOWN Company Information
13.6.2 LAB UNKNOWN Inhalational Isoflurane Product Portfolios and Specifications
13.6.3 LAB UNKNOWN Inhalational Isoflurane Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 LAB UNKNOWN Main Business Overview
13.6.5 LAB UNKNOWN Latest Developments
13.7 Viatris
13.7.1 Viatris Company Information
13.7.2 Viatris Inhalational Isoflurane Product Portfolios and Specifications
13.7.3 Viatris Inhalational Isoflurane Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Viatris Main Business Overview
13.7.5 Viatris Latest Developments
13.8 PT Novell Pharmaceutical
13.8.1 PT Novell Pharmaceutical Company Information
13.8.2 PT Novell Pharmaceutical Inhalational Isoflurane Product Portfolios and Specifications
13.8.3 PT Novell Pharmaceutical Inhalational Isoflurane Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 PT Novell Pharmaceutical Main Business Overview
13.8.5 PT Novell Pharmaceutical Latest Developments
13.9 Sedana Medical
13.9.1 Sedana Medical Company Information
13.9.2 Sedana Medical Inhalational Isoflurane Product Portfolios and Specifications
13.9.3 Sedana Medical Inhalational Isoflurane Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Sedana Medical Main Business Overview
13.9.5 Sedana Medical Latest Developments
13.10 Lunan Beite
13.10.1 Lunan Beite Company Information
13.10.2 Lunan Beite Inhalational Isoflurane Product Portfolios and Specifications
13.10.3 Lunan Beite Inhalational Isoflurane Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Lunan Beite Main Business Overview
13.10.5 Lunan Beite Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.